Compare CLFD & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLFD | AUTL |
|---|---|---|
| Founded | 1979 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | 752 |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.2M | 407.2M |
| IPO Year | 1995 | 2025 |
| Metric | CLFD | AUTL |
|---|---|---|
| Price | $30.38 | $1.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $43.50 | $8.50 |
| AVG Volume (30 Days) | 169.2K | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,034,000.00 | $10,120,000.00 |
| Revenue This Year | $11.64 | $80.32 |
| Revenue Next Year | $22.30 | $53.96 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 9.51 | ★ 496.00 |
| 52 Week Low | $23.76 | $1.15 |
| 52 Week High | $46.76 | $2.70 |
| Indicator | CLFD | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 57.62 | 46.04 |
| Support Level | $28.94 | $1.22 |
| Resistance Level | $30.99 | $1.52 |
| Average True Range (ATR) | 1.63 | 0.08 |
| MACD | 0.47 | 0.01 |
| Stochastic Oscillator | 67.44 | 28.99 |
Clearfield Inc designs, manufactures, and distributes fiber protection, fiber management, and fiber delivery solutions to enable rapid and cost-effective fiber-fed deployment throughout the broadband service provider space prominently across North America. Its 'fiber to anywhere' platform serves the requirements of Community Broadband customers, Multiple System Operators, Large Regional Service Providers, National Carriers, and International customers (including Europe, Canada, Mexico, and Caribbean Markets). Its product offerings include Accessories, Cassettes, Cable & Drop Assemblies, Frames & Panels, Microducts, Optical Components, etc. The company derives the majority of its revenue from the United States.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.